PHAXIAM Therapeutics Stock (NASDAQ:ERYP)
Previous Close
$0.77
52W Range
$0.30 - $1.47
50D Avg
$0.86
200D Avg
$0.74
Market Cap
$47.38M
Avg Vol (3M)
$148.59K
Beta
2.13
Div Yield
-
ERYP Company Profile
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ENOB | Renovaro Biosciences Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| NTRB | Nutriband Inc. |
| IKNA | Ikena Oncology, Inc. |
| XCUR | Exicure, Inc. |
| SRZN | Surrozen, Inc. |
| XRTX | XORTX Therapeutics Inc. |
| HCWB | HCW Biologics Inc. |
| SNGX | Soligenix, Inc. |
| GNFT | Genfit S.A. |
| UNCY | Unicycive Therapeutics, Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| ADXN | Addex Therapeutics Ltd |
| MOLN | Molecular Partners AG |
| ELYM | Eliem Therapeutics, Inc. |